» Articles » PMID: 12613234

Evaluation of Outpatient Adverse Drug Reactions Leading to Hospitalization

Overview
Date 2003 Mar 5
PMID 12613234
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Outpatient adverse drug reaction (ADR)related hospitalization through the emergency department of a nonprofit hospital and the contributing factors are reviewed. Patients who were hospitalized because of suspected ADRs were selected from daily admissions reports and patient medication profiles from 1997 and 1998 by the pharmacy department of a nonprofit community teaching hospital. Hospital charges for individual patients were obtained from the institution's accounting system. Suspected drugs, their therapeutic class, and the organ systems involved in the ADRs were identified. A total of 191 patients who had a complete medical history and cost information were included in the study. Of those patients, 56% were female, and 45% of the patients were 75 years of older. The average hospital charge per ADR patient was $9491. Room and board accounted for more than 50% of total charges. The average length of stay for study patients was 8.0 +/- 10.3 days. Major therapeutic classes implicated in ADRs included antidiabetic agents (27.8%), anticoagulants (15.2%), anticonvulsants (10.0%), beta-blockers (7.9%), and angiotensin-converting-enzyme inhibitors (7.9%). Organ systems most commonly involved in ADR admissions were the endocrine (30.9%) and cardiovascular (24.1%) systems. The implicationed therapeutic groups and organ systems exhibited a different pattern from those of earlier ADR studies. The elderly and the poor are most affected by ADRs. The availability of new drugs and the shift in disease treatment necessitate the continuous monitoring of new ADRs. Patients and family members should be integral components of a multidisciplinary strategy for minimizing the personal and social impact of ADRs.

Citing Articles

Pharmacovigilance practice among pediatric neurologists from Poland and Germany.

Kopciuch D, Kus K, Niskiewicz I, Flicinski J, Zaprutko T, Ratajczak P BMC Med Educ. 2023; 23(1):547.

PMID: 37528387 PMC: 10394771. DOI: 10.1186/s12909-023-04542-4.


Neurologists' Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients-Comparative Analysis from Poland and Egypt.

Kopciuch D, Kamal N, Kamal N, Hamdy N, Paczkowska A, Zaprutko T Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409851 PMC: 8998900. DOI: 10.3390/ijerph19074169.


Cutaneous Adverse Drug Reactions in a Tertiary Teaching Hospital: A Prospective, Observational Study.

Jadhav A, Patil S, Manchanda I, Hasija R, Patil A Indian J Dermatol. 2022; 66(5):573.

PMID: 35068528 PMC: 8751732. DOI: 10.4103/ijd.ijd_874_20.


Medication-related adverse events in health care-what have we learned? A narrative overview of the current knowledge.

Laatikainen O, Sneck S, Turpeinen M Eur J Clin Pharmacol. 2021; 78(2):159-170.

PMID: 34611721 PMC: 8748358. DOI: 10.1007/s00228-021-03213-x.


Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.

Zhou Z, Hultgren K JMIR Public Health Surveill. 2020; 6(3):e19266.

PMID: 32996889 PMC: 7557434. DOI: 10.2196/19266.